Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu-osler disease

被引：27

作者：

Guldmann, Romain ^{[1
]}

Dupret, Agnes

Nivoix, Yasmine ^{[2
]}

Schultz, Philippe

Debry, Christian

机构：

[1] Hop Hautepierre, Hop Univ Strasbourg, Serv Otorhinolaryngol & Chirurg Cervico Faciale, F-67000 Strasbourg, Alsace, France

[2] Hop Hautepierre, Hop Univ Strasbourg, Dept Pharm, F-67000 Strasbourg, Alsace, France

来源：

LARYNGOSCOPE | 2012年 / 122卷 / 05期

关键词：

Rendu-Osler; hereditary hemorrhagic telangiectasia; epistaxis; treatment; bevacizumab; Level of Evidence: 4; HEREDITARY HEMORRHAGIC TELANGIECTASIA;

D O I：

10.1002/lary.23230

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Objectives/Hypothesis: To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu-Osler disease. Study Design: Prospective. Methods: A preliminary, prospective, review board-approved study was conducted on six patients with Rendu-Osler disease who received 10 treatment courses of 50 mg bevacizumab. Monthly follow-up was based on the epistaxis severity score (ESS), with adverse effects being reported. Results: Ten treatment courses were administered to six patients, with a mean follow-up period of 2.8 months. A statistically significant decrease in mean ESS was observed at 1 month (P < .001) and 2 months (P < .005), whereas a nonsignificant decrease was found at 3 months (P = .07). A nonsignificant decline in mean ESS was detected at 1 month in patients with ESS >= 7 at baseline. No adverse effects were reported. Conclusions: The intranasal spray application of 50 mg bevacizumab was found to be an effective symptomatic treatment over a period of 2 months for patients with a pretreatment ESS of < 7, with no adverse effects being noted.

引用

页码：953 / 955

页数：3

共 15 条

[1] Safety of Intranasal Bevacizumab (Avastin) Treatment in Patients with Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis [J].

Chen, Sonia ;

Karnezis, Tom ;

Davidson, Terence M. .

LARYNGOSCOPE, 2011, 121 (03) :644-646

[2] Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab [J].

Flieger, Dimitri ;

Hainke, Sabine ;

Fischbach, Wolfgang .

ANNALS OF HEMATOLOGY, 2006, 85 (09) :631-632

[3] Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration A Multicenter, Retrospective Study [J].

Fong, Donald S. ;

Custis, Peter ;

Howes, Jennifer ;

Hsu, Jin-Wen .

OPHTHALMOLOGY, 2010, 117 (02) :298-302

[4]

Geisthoff UW, 2002, HNO, V50, P114, DOI 10.1007/s001060100537

[5] CURRENT CONCEPTS - HEREDITARY HEMORRHAGIC TELANGIECTASIA [J].

GUTTMACHER, AE ;

MARCHUK, DA ;

WHITE, RI .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (14) :918-924

[6] An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia [J].

Hoag, Jeffrey B. ;

Terry, Peter ;

Mitchell, Sally ;

Reh, Douglas ;

Merlo, Christian A. .

LARYNGOSCOPE, 2010, 120 (04) :838-843

[7] Efficacy of Intranasal Bevacizumab (Avastin) Treatment in Patients with Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis [J].

Karnezis, Tom T. ;

Davidson, Terence M. .

LARYNGOSCOPE, 2011, 121 (03) :636-638

[8] Has Bevacizumab (Avastin) Given Extra Therapeutic Gain in Metastatic Colorectal Cancer and Malignant Brain Gliomas? Systematic Review Answering this Question [J].

Koukourakis, Georgios V. .

RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2012, 6 (01) :70-77

[9] Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia [J].

Lund, VJ ;

Howard, DJ .

JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1997, 111 (01) :30-33

[10]

Sadick H, 2005, INT J MOL MED, V15, P591

← 1 2 →